Codexis has a proprietary protein engineering platform to develop proteins synthesized through cellular fermentation. Codexis revenues are generated through licensing the company’s proprietary protein engineering platform (CodeEvolver®) and through the development of ingredients, industrial enzymes and molecular diagnostics.

In 2020, Codexis entered into a joint partnership agreement with DNA synthesis company, Molecular Assemblies. Through the partnership Codexis purchased $1 million in Series A preferred stock of Molecular Assemblies. The two companies are leveraging the Codexis CodeEvolver® protein engineering platform to develop custom designed enzymes for DNA synthesis. DNA Synthesis has historically been done through chemical processing. Molecular Assemblies is working on synthesizing DNA enzymatically, which enables longer gene lengths and higher accuracy as opposed to chemical synthesis (requires harsh solvents and cannot stitch longer gene lengths). The possibilities to create larger amounts of high-quality DNA enables more advancements in synthetic biology innovations in agriculture, textiles and material sectors. The market for traditional chemical DNA synthesis today is about $2 billion annually (enzymatically synthesized DNA is not yet on the market.